Tag Archives: The Stem Cell Blog

Expert Highlights CAR T-Cell Breakthroughs – OncLive

OncLiveExpert Highlights CAR T-Cell BreakthroughsOncLiveThe oncology community saw the first FDA approval of a chimeric antigen receptor (CAR) T-cell therapy in August 2017, when tisagenlecleucel (Kymriah) was approved for the treatment of patients up … Continue reading

AvidBiotics split forms CAR-T and antibiotic specialists – FierceBiotech

FierceBiotechAvidBiotics split forms CAR-T and antibiotic specialistsFierceBiotech"We have developed a CAR-T cell that is completely inert until it binds to a bispecific antibody, also developed by us, that we call a MicAbody," he tells Fierc… Continue reading

AvidBiotics split forms CAR-T and antibiotic specialists – FierceBiotech

FierceBiotech

AvidBiotics split forms CAR–T and antibiotic specialists FierceBiotech Xyphos has its own spin on the CAR-T approach to cancer immunotherapy, which are targeted towards a single tumor-associated target. In contrast, the biotech’s platform combines the modified T cells used in this type of treatment with bispecific … California upstart Xyphos wants to tackle CAR–T’s big problemsEndpoints News AvidBiotics Splits into Two Biotechnology Companies Each Developing its Distinct Technology PlatformPR Newswire (press release) all 3 news articles »

FierceBiotech

AvidBiotics split forms CAR-T and antibiotic specialists | FierceBiotech FierceBiotech Bay area biotech AvidBiotics has decided that its two development programs in CAR-T and microbiome-driven antibiotics would do better as separate … California upstart Xyphos wants to tackle CAR–T’s big problemsEndpoints News all 3 news articles »

Peptide vehicle drives Crispr delivery of Cas9 into cells Chemistry World Cas9 is a large RNA-guided DNA endonuclease enzyme that is responsible for accurately recognising and cutting the desired sequence of DNA in a cell’s genome during the gene editing process known as Crispr. At the moment, Crispr scientists typically …

FierceBiotech

Bluebird’s tweaked sickle cell gene therapy clears early test FierceBiotech Bluebird bio has posted early clinical data suggesting work to rescue its sickle cell gene therapy may pay off. The tweaked gene therapy triggered a jump in the proportion of vector-positive cells in the two patients treated so far, raising hopes … Bluebird marks progress on Lentiglobin gene therapyBioPharma Dive #ASH17: Bluebird touts early signs that its new-and-improved sickle cell gene therapy is workingEndpoints News Gene Therapy in Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease and bb2121 in Relapsed …Business Wire (press release) Dispatch Tribunal all 43 news articles »

Endpoints News

Juno Therapeutics (JUNO) to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH StreetInsider.com “The presentations at ASH will showcase promising data coming from our pipeline of CD19- and BMCA-directed CAR T cell product candidates,” said Sunil Agarwal, M.D., Juno’s President of Research and Development. “Results from the ongoing … #ASH17: The big loser in CAR–T, Juno is making a bid to seize the fast lane to frontrunner statusEndpoints News Head-To-Head Contrast: Juno Therapeutics (NASDAQ:JUNO) versus Its RivalsWeek Herald all 24 news articles »

Endpoints News

Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH Business Wire (press release) “The presentations at ASH will showcase promising data coming from our pipeline of CD19- and BMCA-directed CAR T cell product candidates,” said Sunil Agarwal, M.D., Juno’s President of Research and Development. “Results from the ongoing … Head-To-Head Contrast: Juno Therapeutics (NASDAQ:JUNO) versus Its RivalsWeek Herald all 30 news articles »